| 3364 |
National Human Genome Research Institute |
Html |
null |
FAQ About Newborn Screening |
Newborn screening tests use a dried blood sample collected during the first week after birth to measure the presence of disease biomarkers (a measurable substance or characteristic that is indicative of a disease). |
|
|
CLICK HERE |
| 15538 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
NIAID's Programs on Asthma in the Inner City |
Recognizing that asthma severity in inner-city children is disproportionately high, NIAID has sponsored research to reduce the public health burden that asthma presents in inner-city populations. Beginning in 1991, NIAID has supported three consecutive inner-city asthma research programs, which have been successful in reducing asthma severity in children. |
| inner-city populations | 0.579525 |
| Morgan WJ | 0.496915 |
| cockroach allergen | 0.471241 |
| inner-city children. | 0.516784 |
| asthma severity | 0.746089 |
| inner-city adolescents | 0.569622 |
| environmental intervention study | 0.506189 |
| clinical trials | 0.457073 |
| Infectious Diseases networks | 0.482159 |
| asthma exacerbations | 0.604543 |
| asthma attacks | 0.618501 |
| Gergen PJ | 0.506952 |
| City Anti-IgE Therapy | 0.499916 |
| asthma | 0.9777 |
| Pongracic JA | 0.498 |
| Szefler SJ | 0.504609 |
| Busse WW. Management | 0.518055 |
| Asthma Control Evaluation | 0.678562 |
| asthma treatment guidelines | 0.681693 |
| Gruchalla RS | 0.496061 |
| Allergy Clin Immunol. | 0.483813 |
| Busse WW. | 0.518705 |
| asthma management | 0.634222 |
| omalizumab | 0.464849 |
| severe allergic asthma | 0.661933 |
|
| asthma morbidity | 0.639521 |
| ICAC investigators | 0.510592 |
| CA. Randomized trial | 0.488723 |
| guidelines-based asthma therapy | 0.667931 |
| asthma presents | 0.660928 |
| nitric oxide level | 0.504737 |
| William Busse | 0.501488 |
| follow-on clinical trial | 0.490114 |
| asthma treatment | 0.724256 |
| public health burden | 0.502806 |
| exhaled nitric oxide | 0.589522 |
| at-risk children | 0.467554 |
| inner city | 0.546793 |
| Liu AH | 0.496615 |
| Teach SJ | 0.501285 |
| clinical guidelines | 0.486081 |
| principal investigators | 0.485986 |
| Asthma counselors | 0.64051 |
| ICAC program | 0.497263 |
| inner-city asthma research | 0.793594 |
| basic research sites | 0.543997 |
| year-long study | 0.459719 |
| inner-city children | 0.771731 |
| asthma symptoms | 0.641572 |
|
CLICK HERE |
| 15540 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
NIAID Paylines -- NIAID Research Funding |
Fiscal year paylines for all award types. |
| Final NIAID Paylines | 0.905895 |
| POs contact information | 0.229921 |
| interim paylines | 0.666704 |
| success rates | 0.214968 |
| Email Alerts | 0.25735 |
| NIAID funds | 0.432012 |
|
| Research Project Success | 0.236611 |
| program officer | 0.217587 |
| overall impact/priority score | 0.255863 |
| initial paylines | 0.594349 |
| Research Portfolio Online | 0.237047 |
|
CLICK HERE |
| 15541 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Sample Applications and Summary Statements -- NIAID Research Funding |
Sample Applications and Summary Statements and a list of all samples and examples that are part of the grant application from NIAID and NIH -- NIAID Research Funding |
| application format | 0.907608 |
| grantee organization | 0.765229 |
| funding opportunity | 0.767168 |
| Dr. Andrew Hemmert | 0.871038 |
| new research projects | 0.933476 |
| feasibility studies | 0.741985 |
| R33 phase | 0.759832 |
| ethnic groups | 0.738984 |
| sound examples | 0.760636 |
| sample applications | 0.791811 |
| widely anticipated resource | 0.905833 |
| research community | 0.804124 |
| major recipients | 0.749258 |
| independent research career | 0.905416 |
| small-scale research projects | 0.918897 |
| predoctoral students | 0.755344 |
| good grantsmanship | 0.776715 |
| limited resources | 0.753355 |
| Research Enhancement Award | 0.912673 |
| grant renewal | 0.750527 |
| model systems | 0.747297 |
| R21 phase | 0.802738 |
| original grant application. | 0.876558 |
| exceptional applications | 0.795607 |
|
| two-phased award | 0.744601 |
| latest application format | 0.89336 |
| summary statements | 0.774822 |
| possible transition | 0.745699 |
| new samples | 0.775894 |
| milestone-driven exploratory | 0.747537 |
| new investigators | 0.919996 |
| domestic small businesses | 0.862103 |
| research training | 0.778846 |
| NIH example forms | 0.929049 |
| Dr. Hemmert | 0.748615 |
| nonprofit educational purposes | 0.880734 |
| short period | 0.753535 |
| Small Business Programs | 0.860069 |
| R21 funds novel | 0.915071 |
| research environment | 0.789167 |
| NIH support | 0.763875 |
| disadvantaged backgrounds | 0.737728 |
| *Dr. Mark Poritz | 0.868098 |
| biomedical research | 0.780582 |
| Dr. Poritz | 0.748763 |
| educational institutions | 0.749988 |
| program supports | 0.759468 |
| scientific ideas | 0.747402 |
|
CLICK HERE |
| 15545 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Methicillin-Resistant Staphylococcus aureus MRSA, Antimicrobial Resistance |
NIAID conducts and supports research on methicillin-resistant Staphylococcus aureus, MRSA--drug-, or antimicrobial-, resistant bacteria that has become a serious public health concern. |
| Allergy | 0.341577 |
| Require | 0.335974 |
| Experts | 0.328592 |
| Research > Antimicrobial | 0.486656 |
| Pathway | 0.34693 |
| methicillin-resistant staphylococcus aureus | 0.971182 |
| controllable nuisance | 0.508668 |
| HIV Vaccine | 0.518468 |
| NIAID-Supported Institutions | 0.464562 |
| Research > NIAID | 0.500955 |
| MRSA | 0.488992 |
| News | 0.326356 |
| new strains | 0.473848 |
|
| Universal Influenza Vaccine | 0.682447 |
| HIV/AIDS Pandemic Likely | 0.665604 |
| public health concern | 0.611156 |
| National Institute | 0.496139 |
| NIH | 0.350088 |
| allergic diseases | 0.501528 |
| severe infections | 0.473944 |
| Role | 0.327169 |
| Infectious Diseases | 0.524019 |
| decades | 0.338877 |
| hospital-acquired infection | 0.507902 |
| Durable End | 0.489538 |
|
CLICK HERE |
| 15548 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Tuberculosis TB, NIAID, NIH |
NIAID is examining TB at its fundamental levels through research to develop faster diagnosis, better vaccines, and shorter treatment times. |
| animal models | 0.484339 |
| treatment strategies | 0.479645 |
| new TB drug | 0.750789 |
| drug-resistant strains | 0.584127 |
| multidrug-resistant TB | 0.705257 |
| optimal drug combinations | 0.547291 |
| TB disease | 0.789313 |
| research findings | 0.480296 |
| severe airborne disease | 0.575915 |
| research | 0.505253 |
| new candidate drugs | 0.571748 |
| death worldwide | 0.485014 |
| novel TB drugs | 0.766874 |
| national history | 0.484991 |
| candidate drugs | 0.572469 |
| active TB disease | 0.746928 |
| TB deaths | 0.714042 |
| major causes | 0.487119 |
| MedlinePlus tuberculosis site | 0.583865 |
| genetic drug | 0.486206 |
| comprehensive portfolio | 0.485226 |
| TB bacterium | 0.688383 |
| latent infections | 0.478461 |
| middle-income countries | 0.49248 |
|
| risk factors | 0.478783 |
| World Health Organization | 0.559465 |
| research infrastructure | 0.479568 |
| early TB disease | 0.745692 |
| NIAID | 0.606471 |
| diagnostic potential | 0.480354 |
| people | 0.530993 |
| TB | 0.982786 |
| biomedical research | 0.486422 |
| new TB drugs | 0.754513 |
| HIV deaths | 0.484548 |
| Mycobacterium tuberculosis | 0.614224 |
| private industry | 0.478347 |
| public health practices | 0.540649 |
| TB diagnosis | 0.691172 |
| clinical studies | 0.55766 |
| prevention strategies | 0.478336 |
| NIAID priority | 0.54559 |
| vaccine clinical trials | 0.538763 |
| Mtb | 0.530457 |
| drug resistance | 0.554266 |
| causative agent | 0.484545 |
| basic research | 0.485797 |
|
CLICK HERE |
| 15552 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Dengue Fever, NIAID, NIH |
NIAID health and research information on dengue fever |
| dengue animal models | 0.637025 |
| related dengue viruses | 0.700576 |
| New research findings | 0.39085 |
| point-of-care machine | 0.349211 |
| dengue infection | 0.729539 |
| economic burden | 0.353666 |
| dengue vaccines | 0.665616 |
| muscle pain | 0.354058 |
| rapid dengue diagnosis | 0.618858 |
| small molecule drugs | 0.38263 |
| Western hemisphere | 0.353064 |
| clinical trials | 0.351867 |
| live-attenuated dengue viruses | 0.642326 |
| dengue-endemic countries | 0.348281 |
| dengue research projects | 0.662649 |
| diagnostic tests | 0.396946 |
| specific diagnostic tests | 0.387357 |
| human trials | 0.348533 |
| community-based prevention programs | 0.394083 |
| vaccine approach | 0.349325 |
| recombinant version | 0.351126 |
| viral factors | 0.354135 |
| dengue fever | 0.846342 |
| laboratory-based international surveillance | 0.396575 |
| rapid diagnostic tests | 0.391709 |
|
| healthcare providers | 0.353653 |
| treatment strategies | 0.350986 |
| United States | 0.35404 |
| global health threat | 0.393267 |
| dengue shock syndrome | 0.744003 |
| NIAID researchers | 0.395179 |
| infected people | 0.351147 |
| different viral dengue | 0.634725 |
| public health | 0.35259 |
| NIAID research priorities | 0.443797 |
| dengue disease | 0.600916 |
| recombinant proteins | 0.349944 |
| Health experts | 0.357315 |
| severe forms | 0.399676 |
| dengue | 0.999102 |
| viral proteins | 0.352028 |
| MedlinePlus dengue site | 0.654335 |
| viral vectors | 0.355429 |
| basic research activities | 0.394177 |
| dengue hemorrhagic fever | 0.763697 |
| NIAID projects | 0.394476 |
| new treatment options | 0.386411 |
| effective vaccine | 0.349229 |
| infectious disease | 0.367495 |
|
CLICK HERE |
| 15553 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Autoimmune Lymphoproliferative Syndrome (ALPS) |
General and NIAID research information about Autoimmune lymphoproliferative syndrome (ALPS). |
| red blood cells | 0.498965 |
| Genetics Home Reference | 0.386541 |
| common type | 0.27372 |
| enlarged spleen | 0.273296 |
| treatment strategies | 0.256376 |
| clinical findings | 0.247554 |
| better understanding | 0.262253 |
| inflammatory bowel diseases | 0.386467 |
| primary immune deficiency | 0.43025 |
| normal cell lifecycle | 0.380592 |
| genetic defects | 0.264434 |
| low blood cell | 0.387723 |
| abnormal buildup | 0.395762 |
| low count | 0.525489 |
| common autoimmune diseases | 0.498412 |
| blood cells. | 0.260493 |
| research questions | 0.258643 |
| autoimmune lymphoproliferative syndrome | 0.860748 |
| systemic lupus erythematosus | 0.388262 |
| NIAID researchers | 0.384049 |
| white blood cells | 0.708626 |
| numerous autoimmune problems | 0.563557 |
| lymphoproliferative syndrome site | 0.41581 |
| related disorders | 0.38884 |
|
| major clinical symptoms | 0.374436 |
| NIAID PIDD site | 0.506663 |
| current management | 0.256481 |
| National Library | 0.256237 |
| increased risk | 0.262725 |
| PIDD research | 0.257719 |
| autoimmune diseases | 0.588163 |
| effective treatments | 0.265251 |
| risk factors | 0.248383 |
| white blood cell | 0.447537 |
| cell death | 0.256903 |
| genetic characteristics | 0.264791 |
| patient care | 0.257891 |
| rheumatoid arthritis | 0.249292 |
| rare genetic disorder | 0.433441 |
| ALPS | 0.995498 |
| NIAID focus | 0.38608 |
| FAS gene cause | 0.410071 |
| autoimmune destruction | 0.357642 |
| lymph nodes | 0.291536 |
| FASÂ gene | 0.591557 |
| genome sequencing | 0.254615 |
| debilitating symptoms | 0.274164 |
|
CLICK HERE |
| 15804 |
National Institute of Allergy and Infectious Diseases |
Html |
en |
Food Allergy |
NIAID supports food allergy research, which spans the spectrum from basic research in allergy and immunology to clinical trials that are testing new strategies to treat and prevent food allergy. |
| prevention options | 0.339349 |
| ongoing clinical trials | 0.370651 |
| lead Institute | 0.347558 |
| NIAID-funded scientists | 0.33777 |
| new strategies | 0.345355 |
| current evidence-based recommendations | 0.370416 |
| policy report | 0.342135 |
| immune responses | 0.337553 |
| children | 0.321267 |
| faster rate | 0.335898 |
| observational studies | 0.345615 |
| significant progress | 0.335698 |
| practical ways | 0.34177 |
| National Institutes | 0.383015 |
| risk factors | 0.342668 |
| Personal medical history | 0.374798 |
| NIAID-supported study | 0.337131 |
| important role | 0.337607 |
| eosinophilic esophagitis | 0.3439 |
| United States | 0.385897 |
| allergic conditions | 0.339157 |
| common allergens plays | 0.380868 |
| gut bacteria | 0.371845 |
| Drug Administration | 0.341666 |
| scientific community | 0.339254 |
|
| food allergies | 0.381405 |
| NIAID researchers | 0.401866 |
| allergy clinical trials | 0.47886 |
| life-threatening response | 0.347529 |
| basic studies | 0.337145 |
| early introduction | 0.341065 |
| experimental immunotherapies | 0.343557 |
| new treatments | 0.33937 |
| careful monitoring | 0.340519 |
| active clinical trials | 0.373969 |
| baked milk | 0.396405 |
| NIAID-funded study | 0.336779 |
| comprehensive food allergy | 0.510173 |
| NIAID | 0.483382 |
| food allergy | 0.951641 |
| milk allergy foods | 0.4779 |
| biomedical research | 0.341796 |
| Clinical Immunology | 0.339341 |
| National Academies | 0.341431 |
| food allergy research | 0.643116 |
| family history | 0.340464 |
| oral allergy syndrome | 0.484032 |
| food allergens | 0.388332 |
| expert panel | 0.337968 |
|
CLICK HERE |
| 15981 |
National Institute of Allergy and Infectious Diseases |
Video |
en |
Influenza: Get the (Antigenic) Drift |
Have you ever wondered why you need a flu vaccination each year? The National Institute of Allergy and Infectious Diseases explains the ever-changing nature of influenza viruses. |
| Action MOA Animation | 0.579913 |
| Shomu | 0.416725 |
| Allergy | 0.416577 |
| SwineFlu | 0.416001 |
| Daniel Levy | 0.496516 |
| flutube100 | 0.416238 |
| Osmosis | 0.416074 |
| H1N1 Swine Flu | 0.627108 |
| Unpredictable Threat | 0.498722 |
| flu vaccination | 0.597572 |
| milos velja | 0.493184 |
| World Health Organization | 0.57148 |
| 1918 Flu Pandemic | 0.627835 |
| flu virus mechanism | 0.693678 |
| reverse transcriptase | 0.494547 |
| Duration | 0.949875 |
| Virus Invades | 0.512664 |
| AMAZING DOCUMENTARY | 0.485888 |
| autoplay | 0.453443 |
| HIV life cycle | 0.567135 |
| Carolyn Bertozzi | 0.598025 |
| Infectious Diseases | 0.507143 |
| Influenza H1N1 Mechanism | 0.7022 |
| VIRUS EVOLUTION | 0.501245 |
| antigenic shift | 0.607123 |
|
| influenza | 0.762967 |
| 720p | 0.423131 |
| iBioEducation | 0.42898 |
| Influenza animation | 0.642901 |
| Influenza Pandemics Occur | 0.718554 |
| Biology | 0.416713 |
| video | 0.418444 |
| Genetic Shift | 0.503494 |
| Berkeley/HHMI | 0.429072 |
| ever-changing nature | 0.51424 |
| views | 0.737316 |
| National Institute | 0.509002 |
| Fighting flu | 0.555906 |
| Influenza infection model | 0.670194 |
| Immune Response | 0.487687 |
| David Hager | 0.509045 |
| Scientific Animations | 0.498803 |
| DOCUMENTARY TUBE | 0.482643 |
| NIAID | 0.456714 |
| Influenza Virus Infection | 0.688245 |
| Flu Attack | 0.564409 |
| influenza viruses | 0.646604 |
| Nucleus Medical Media | 0.585917 |
| Million People | 0.484786 |
|
CLICK HERE |